Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Sebivo | Telbivudine | Hepatitis B (chronic) | Do not list | Complete | ||
| Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
| Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | ||
| Xermelo | telotristat | carcinoid syndrome | Do not reimburse | Complete | ||
| Vemlidy | tenofovir alafenamide | Hepatitis B, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | N/A | Complete | ||
| Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete |
Last Updated : April 28, 2024